Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting

Bolt Biotherapeutics, Inc.

Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).
Laura Berner and Brian O'Callaghan elected as Class I directors with 10.6M and 11.2M votes for, respectively.
PricewaterhouseCoopers LLP ratified as independent auditor for FY2025: 23,330,316 votes for.
Annual meeting had 24,362,318 shares represented out of 38,339,697 entitled to vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.